Le Lézard
Classified in: Health, Science and technology
Subject: Funding

CinRx Pharma Announces Additional $73 Million Financing

CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies ("CinCos") focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need.

"Our early financings totaling $103 million supported the construction and progression of our seven-company portfolio. Notably, this included the formation, advancement and exit of CinCor Pharma ahead of its $1.8 billion acquisition, underscoring the success of our incredibly effective team and validation of our efficient business model," said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. "With this infusion of capital, we will continue rapid advancement of existing programs and replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients' quality of life."

CinRx's portfolio of CinCos are managed by a lean team of scientific, technical and drug development experts with decades of experience treating patients and supporting thousands of clinical development programs. Each CinCo was created through a rigorous asset selection process to identify novel therapies with the potential to address significant unmet medical needs and meaningfully reduce disease burden for patients.

About CinRx Pharma:

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx's approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx's central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients' quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

For more information, please visit www.CinRx.com or follow the company on X and LinkedIn.

These press releases may also interest you

at 12:45
SummaryProducts: Dianeal PD4 2.5% Dextrose peritoneal dialysis solution (3,000 mL and 5,000 mL); Physioneal 40 2.27% Glucose peritoneal dialysis solution (2,500 mL)Issue: Health products ? Product safetyWhat to do: Immediately check your stock to see...

at 10:45
Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern...

at 10:30
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equecabtagene Autoleucel (Eque-cel),...

at 10:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and...

at 09:00
The Minister of Labour and Seniors, Seamus O'Regan Jr., and the Minister of Mental Health and Addictions and Associate Minister of Health, Ya'ara Saks, issued the following statement on World Elder Abuse Awareness Day: "Elder abuse is a crime that...

at 09:00
From June 15 to July 15, the premium health supplement brand, Vimergy, will be featured in the Medical Medium created smoothie, available at all Erewhon locations. Created by Medical Medium Anthony William, the smoothie will feature Vimergy Barley...

News published on and distributed by: